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Abstract
Dilated cardiomyopathy (DCM) is a structural heart disease with strong genetic background. Monogenic forms of DCM are
observed in families with mutations located mostly in genes encoding structural and sarcomeric proteins. However, strong
evidence suggests that genetic factors also affect the susceptibility to idiopathic DCM. To identify risk alleles for non-familial
forms of DCM, we carried out a case-control association study, genotyping 664 DCM cases and 1,874 population-based
healthy controls from Germany using a 50K human cardiovascular disease bead chip covering more than 2,000 genes pre-
selected for cardiovascular relevance. After quality control, 30,920 single nucleotide polymorphisms (SNP) were tested for
association with the disease by logistic regression adjusted for gender, and results were genomic-control corrected.
The analysis revealed a significant association between a SNP in HSPB7 gene (rs1739843, minor allele frequency 39%)
and idiopathic DCM (p=1.06610
26, OR=0.67 [95% CI 0.57–0.79] for the minor allele T). Three more SNPs showed
p , 2.21610
25. De novo genotyping of these four SNPs was done in three independent case-control studies of idiopathic
DCM. Association between SNP rs1739843 and DCM was significant in all replication samples: Germany (n=564, n=981
controls, p=2.07610
23, OR=0.79 [95% CI 0.67–0.92]), France 1 (n=433 cases, n=395 controls, p=3.73610
23, OR=0.74
[95% CI 0.60–0.91]), and France 2 (n=249 cases, n=380 controls, p=2.26610
24, OR=0.63 [95% CI 0.50–0.81]). The
combined analysis of all four studies including a total of n=1,910 cases and n=3,630 controls showed highly significant
evidence for association between rs1739843 and idiopathic DCM (p=5.28610
213, OR=0.72 [95% CI 0.65–0.78]). None of
the other three SNPs showed significant results in the replication stage. This finding of the HSPB7 gene from a genetic
search for idiopathic DCM using a large SNP panel underscores the influence of common polymorphisms on DCM
susceptibility.
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Dilated cardiomyopathy (DCM) is a common form of heart
muscle disease with a prevalence of 1:2,500 in the general
population. It represents a major cause of cardiovascular
morbidity and mortality and is characterized by systolic dysfunc-
tion as well as dilation and impaired contraction of the ventricles,
often leading to chronic heart failure and eventually requiring
cardiac transplantation [1]. In about 35% of cases DCM is a
familial disease [2]. However, in the sporadic form of DCM, i. e.
after exclusion of affected family members and all detectable
causes (also called idiopathic DCM), a genetic component is
discussed, but can thus far not be assigned to single gene defects.
Knowledge of genetic risk factors for both, familial and non-
familial forms of DCM is important to initiate treatment prior to
symptomatic onset of the disease, to delay its occurrence or
possibly halt its progression. To date, only a few common
susceptibility alleles for sporadic DCM were identified from
candidate-gene approaches, but could not be confirmed in
replication samples [2,3], this being a common problem of single
gene based analyses [4]. In contrast, unbiased genome-wide
association studies (GWAS) allow the identification of genetic risk
factors even outside of known genes, but higher power is needed to
compensate for multiple testing [5]. No comprehensive GWAS
was performed to date on sporadic form of DCM.
The cardiovascular gene-centric 50K single nucleotide poly-
morphism (SNP) ITMAT-Broad-CARe (IBC) array represents an
established compromise between GWAS and hypothesis-driven
candidate gene approach by analyzing polymorphisms in more
than 2,000 genes known or predicted to be involved in
cardiovascular phenotypes [6].
In this study, we conducted a screening based on the
cardiovascular 50K SNP array with three independent replication
studies to reveal insight in genetic contribution to idiopathic
DCM. The four samples from Germany and France included
1,910 sporadic DCM cases and 3,630 healthy controls individuals.
We identified a common intronic variant in HSPB7, encoding a
cardiovascular small heat shock protein, to be associated with
sporadic form of DCM.
Results
Screening stage
In our screening case-control sample, DCM cases were more
likely men, were slightly younger and less frequently smokers, had
a lower BMI and a higher prevalence of hypertension,
hypercholesterolemia as well as type 2 diabetes (Table 1).
After quality control, 30,920 SNPs were available for analysis with
23,307 independent markers (defined as SNPs with pairwise r
2,0.8
based on linkage disequilibrium (LD) in the control group).
Therefore, we set a significance threshold to 0.05/23,307=2.156
10
26 to account for the multiple testing. In association analyses of this
stage 1 study applying logistic regression adjusted for gender, four
SNPs, namely rs1739843 (HSPB7, intron 2), rs11701453 (RUNX1,
intron 1), rs7597774 (ADD2, intron 1) and rs2229714 (RPS6KA1,3 9
untranslated region) showed a p-value below this threshold
(3.16*10
28,1 . 6 5 * 1 0
27,2 . 0 5 * 1 0
27, and 1.51*10
26, respectively).
Results were similar when additionally adjusting for age (e.g. for
rs1739843 p=2.40*10
28). None of the four polymorphisms showed
deviation from Hardy-Weinberg equilibrium. The lowest p-value for
association with DCM was observed for a SNP located in HSPB7
intron 2 (rs1739843) leading to a protective effect of the minor allele
(OR=0.67 [95% CI 0.58–0.77]). Analysis of the region around the
SNP rs1739843 using HapMap data (release #22) revealed the
Author Summary
Dilated cardiomyopathy is a severe disease of the heart
muscle and often leads to chronic heart failure, eventually
with the consequence of cardiac transplantation. Identifi-
cation of genetic disease markers in at-risk persons could
play an important role in preventive health care. Several
mutations in familial forms of the disease are described.
Here, we examine the role of common genetic variants on
the sporadic form of dilated cardiomyopathy. By screening
about 2,000 candidate genes previously related to
cardiovascular disease in more than 1,900 cases and
3,600 controls, we show that a polymorphism in the HSPB7
gene (rs1739843) is strongly associated with susceptibility
to dilated cardiomyopathy. We also show that the effect
on disease risk is present in both German and French
cohorts. Therefore, this study is an important step towards
revealing insight in the genetic background of the
sporadic form of dilated cardiomyopathy.
Table 1. Characteristics of DCM cases and controls used for initial screening.
Variable DCM cases DCM-free controls p-value
(n=664) (n=1,874)
Gender, % male (n) 85.1 (565) 47.4 (888) ,0.0001
Age at diagnosis/inclusion, years 45.6611.3 (6–70) 62.0610.9 (35–84) ,0.0001
LVEF, % 24.368.7 n. a. -
Hypertension
a,%( n) 96.2 (639) 57.7 (1,076) ,0.0001
Hypercholesterolemia
b,%( n) 38.1 (253) 29.3 (549) ,0.0001
Type 2 diabetes
c,%( n) 20.6 (137) 9.6 (179) ,0.0001
Smoking
d,%( n) 35.1 (233) 50.8 (952) ,0.0001
BMI, kg/m
2 26.564.6 (15.9–46.7) 28.064.5 (16.8–51.4) ,0.0001
Values denote means 6 standard deviations (range) unless indicated otherwise. n. a., not available; LVEF, left ventricular ejection fraction; BMI, body mass index.
aDefined as blood pressure $140/90 mmHg or ongoing antihypertensive therapy.
bDefined as LDL cholesterol $160 mg/dL or intake of lipid lowering medication.
cDefined as self-reported history of diabetes mellitus or intake of antidiabetic medication.
dFormer or current smoking habit including current occasionally smokers.
doi:10.1371/journal.pgen.1001167.t001
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(r
2-value.0.5) (Figure 1A). Nine of these SNPs were present on the
cardiovascular 50K array after quality control and were located in
HSPB7 gene as well as two genes downstream, CLCNKA and
CLCNKB (Figure 1B; Table S1).
In this sample, the genomic inflation factor l was 1.285 for the
highest 90% of the 30,920 observed p-values. When correcting
rs1739843 for this l factor, the p-value was 1.06*10
26 and
OR=0.67 [95% CI 0.57–0.79] (Table 2).
Replication
The four SNPs with uncorrected p,2.15610
26 in the initial
scan (rs1739843, rs11701453, rs7597774 and rs2229714) were
analyzed using logistic regression adjusted for gender in three
Figure 1. Linkage disequilibrium (LD) structure of HSPB7 genomic region and association results. (A) LD measurement (r
2) of HapMap
data on CEU samples (release #22) in relation to rs1739843. On each side of the SNP, 100 kb were analyzed and plotted (n=138 SNPs). (B) SNPs
(n=9, Table S1; *, two SNPs) in HSPB7 gene region on the 50K gene-centric human CVD bead chip after quality control and l-corrected association
results in 664 DCM cases and 1,874 controls. Plots were generated by using the SNAP tool [33].
doi:10.1371/journal.pgen.1001167.g001
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DCM patients and n=981 controls were genotyped for the four
SNPs. Marker rs1739843 showed strong association with DCM
(p=2.07*10
23, OR=0.79 [95% CI 0.67–0.92]). Conversely, for
rs2229714 (p=0.075, OR=1.20 [95% CI 0.98–1.47]),
rs11701453 (p=0.373, OR=1.09 [95% CI 0.90–1.31]) and
rs7597774 (p=0.621, OR=1.04 [95% CI 0.89–1.22]) the initial
association results were not replicated. Second, a French
replication sample (France 1) consisted of n=433 cases and
n=395 controls. Only rs1739843 showed association with DCM
after adjustment for gender (p=3.73*10
23, OR=0.74 [95% CI
0.60–0.91]). For the other SNPs, no significant association was
seen in this sample. Third, in an independent second French
replication sample (France 2), again only rs1739843 showed
association with DCM after adjustment for gender (p=2.26*10
24,
OR=0.63 [95% CI 0.50–0.81]). Replication results are summa-
rized in Table 2. None of the four polymorphisms showed
deviation from Hardy-Weinberg equilibrium in any replication
samples.
In a combined analysis of the screening step, corrected for the l
factor of 1.285, and the three follow-up studies (n=5,540), the
SNP rs1739843 reached a p-value of 5.28*10
213 (OR=0.72 [95%
CI 0.65–0.78]) for association with idiopathic DCM (Table 2,
Figure 2). There was no between-study heterogeneity for this effect
(I
2=6.9%, p=0.36).
Resequencing
To reveal potential causal variants, the coding region of HSPB7
was resequenced in a total of 48 DCM patients. We detected three
known synonymous variants (rs945416, rs732286 and rs1739840).
The synonymous variants rs945416 (position 19, serine) and
rs732286 (position 33, alanine) are in high LD with rs1739843
(r
2=0.96, HapMap CEU data release #24). SNP rs1739840
(position 117, threonine) is not available in HapMap. In the initial
sample of 664 DCM patients, all three synonymous polymor-
phisms are in perfect LD to each other and to rs1739843 as shown
by genotyping. Neither missense nor splice site de novo mutations
were identified by sequencing. Synonymous SNP rs11807575, as
well as non-synonymous variants rs77021870 and rs74626772
were listed in databases, but not found to be polymorphic in our
sample.
Analysis of DCM candidate genes
Since the design of the 50K human gene-centric bead chip (IBC
array) aims at a large-scale gene-based approach, we screened
candidate genes which are known for or potentially involved in
Table 2. Association of SNPs showing p-values , 2610
26 in the initial screening sample and follow-up in three independent
replication samples analyzed by logistic regression adjusted for gender.
p-value (OR [95% CI]) in screening and replication samples
Combined
analysis
(n=5,540)
SNP ID
Nearest gene
(RefSeq, SNP
location)
Minor allele
(frequency)
a
Screening
Germany (n=664
cases, n=1,874
controls)
b
Replication
Germany (n=564
cases, n=981
controls)
Replication
France 1 (n=433
cases, n=395
controls)
Replication
France 2 (n=249
cases, n=380
controls)
p-value (OR
[95% CI])
b
rs1739843 HSPB7 (NM_
014424.4, intron 2)
T (0.39) 1.06*10
26 (0.67
[0.57–0.79])
2.07*10
23 (0.79
[0.67–0.92])
3.73*10
23 (0.74
[0.60–0.91])
c
2.26*10
24 (0.63
[0.50–0.81])
5.28*10
213 (0.72
[0.65–0.78])
rs11701453 RUNX1 (NM_
001754.4, intron 1)
C (0.21) 3.88*10
26 (1.52
[1.27–1.82])
0.373 (1.09
[0.90–1.31])
0.283 (0.88
[0.69–1.12])
0.723 (0.95
[0.72–1.25])
9.23*10
23 (1.15
[1.04–1.28])
rs7597774 ADD2 (NM_
017488.2, intron1)
C (0.36) 4.60*10
26 (1.44
[1.23–1.69])
0.621 (1.04
[0.89–1.22])
0.405 (0.92
[0.74–1.13])
0.655 (1.06
[0.83–1.35])
6.16*10
23 (1.14
[1.04–1.24])
rs2229714 RPS6KA1
(NM_002953.3, 39
UTR)
A (0.15) 2.21*10
25 (1.54
[1.26–1.88])
0.075 (1.20
[0.98–1.47])
0.543 (1.10
[0.82–1.47])
0.660 (0.92
[0.64–1.32])
1.98*10
24 (1.26
[1.11–1.42])
OR, odds ratio; CI, confidence interval; UTR, untranslated region.
aFor screening case-control sample.
bInitial screening sample corrected for l=1.285; combined analysis based on the beta-estimates of all four studies using a fixed effect model.
cProxy SNP rs1763601 was genotyped (HapMap phase 2 release 24: r
2 between rs1739843 and rs1763601=1.0).
doi:10.1371/journal.pgen.1001167.t002
Figure 2. Forest plot for rs1739843 in initial screening sample (l-corrected) and three replication samples (Germany, France 1, and
France 2), together with results from the combined analysis.
doi:10.1371/journal.pgen.1001167.g002
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information on 30,920 SNPs. We established a list of previously
reported genes for DCM by searching PubMed and OMIM
databases (http://www.ncbi.nlm.nih.gov/) for ‘‘CARDIOMYOP-
ATHY, DILATED’’ and ‘‘GENETIC’’. A total of 315 SNPs
including 234 independent SNPs (defined as SNPs with pairwise
Table 3. Candidate gene approach on DCM causing or susceptibility genes.
Gene Protein Chromosome
Number of SNPs
analyzed in gene
region +/210 kb
before/after
quality control Best p-value
a
pcorr Bonferroni
region-wide
after quality
control OMIM References
b
ABCC9 (SUR2A) ATP-binding cassette transporter
sub-family C member 9
12p12.1 34/25 0.0004 0.010 601439 [20,34]
ACTC1 Actin, alpha, cardiac muscle 1 15q14 13/13 0.1165 1 102540 [20,35]
ACTN2 Actinin, alpha-2 1q43 0 - - 102573 [20,36]
ANKRD1 Ankyrin repeat domain-containing
protein 1, cardiac (CARP)
10q23.31 0 - - 609599 [37,38]
CSRP3 Cysteine and glycine-rich protein 3
(muscle LIM protein)
11p15.1 13/11 0.0115 0.123 600824 [20,39]
DES Desmin 2q35 5/3 0.0072 0.022 125660 [20,40]
DMD Dystrophin Xp21.2-p21.1 4/4 0.1504 0.602 300377 [20,41,42]
DSG2 Desmoglein-2 18q12.1 24/16 0.1820 1 125671 [43]
EYA4 Eyes absent homolog 4 6q23.2 0 - - 603550 [44]
FKTN (FCMD) Fukutin 9q31.2 0 - - 607440 [45]
HBEGF Heparin-binding EGF-like growth factor 5q31.3 11/7 0.1160 0.812 126150 [46]
IK IK cytokine, down-regulator of HLAII
(protein RED)
5q31.3 0 - - 600549 [46]
LAMA4 Laminin subunit alpha-4 6q21 0 - - 600133 [47]
LDB3 LIM domain-binding protein 3 (Cypher) 10q23.2 0 - - 605906 [20]
LMNA Lamin A/C 1q22 7/7 0.3028 1 150330 [20,48]
MYBPC3 Myosin-binding protein C, cardiac 11p11.2 19/9 0.0112 0.101 600958 [20,49]
MYH6 Myosin-6 14q11.2 1/1 0.0049 0.005 160710 [20,50]
MYH7 Myosin-7 14q11.2 3/3 0.2691 0.807 160760 [20,51]
NEBL Nebulette (Actin-binding Z-disk protein) 10p12.31 2/2 0.3159 0.632 605491 [52]
NEXN Nexilin (F actin binding protein) 1p31.1 6/5 0.4556 1 613121 [53]
PLN Phospholamban 6q22.31 4/3 0.0465 0.140 172405 [20,54,55]
PSEN1 Presenilin-1 14q24.2 0 - - 104311 [56]
PSEN2 Presenilin-2 1q42.13 8/6 0.2753 1 600759 [56]
RBM20 Ribonucleic acid binding motif protein 20 10q25.2 0 - - 613171 [57]
SCN5A Sodium channel protein type 5 subunit
alpha
3p22.2 51/42 0.0291 1 600163 [58]
SGCD Sarcoglycan delta 5q33.3 84/64 0.0182 1 601411 [20,59]
SRA1 Steroid receptor RNA activator 1 5q31.3 0 - - 603819 [46]
TAZ Tafazzin Xq28 4/4 0.1633 0.653 300394 [20,60,61]
TCAP Telethonin 17q12 8/5 0.4175 1 604488 [2,62]
TMPO Thymopoietin 12q23.1 12/8 0.0260 0.208 188380 [63]
TNNC1 Troponin C, slow skeletal and cardiac
muscles
3p21.1 4/4 0.0794 0.318 191040 [64]
TNNI3 Troponin I, cardiac muscle 19q13.42 14/10 0.0266 0.266 191044 [20,65]
TNNT2 Troponin T, cardiac muscle 1q32.1 15/12 0.0081 0.097 191045 [20,51]
TPM1 Tropomyosin alpha-1 15q22.2 11/10 0.0018 0.018 191010 [20,66]
TTN Titin 2q31.2 43/28 0.0404 1 188840 [20,67]
VCL Vinculin 10q22.2 19/13 0.1731 1 193065 [20,68]
aLogistic regression adjusting for gender.
bReview, original publication(s).
Details are listed in Table S2.
doi:10.1371/journal.pgen.1001167.t003
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2,0.8 based on LD in the control group) were located in or near
(+/210kb) the chosen candidate genes, representing 1.01% of
array content. DCM association results for these SNPs were
obtained from our screening study on 664 cases and 1,874 controls
(Table 3, more details in Table S2). On a single candidate gene
level, polymorphisms in or near ABCC9, DES, MYH6 and TPM1
showed nominal significance after Bonferroni correction for the
number of SNPs tested in gene regions (p=0.010, p=0.022,
p=0.005 and p=0.018, respectively). However, none of these
SNPs remained significant after correction for the 234 indepen-
dent markers tested in this DCM candidate gene approach. Our
study was powered to detect moderate to large effects (e. g. for
OR.1.3 and MAF=30% or OR.1.5 and MAF=20% or
OR.1.7 and MAF=10%, the power was 56%, 96% and 97% for
two-sided p,0.05/234=2.14*10
24, respectively).
Discussion
In the present case-control study, we evaluated the relationship
of common SNPs with sporadic DCM using a large-scale
screening approach. Our comprehensive strategy set out to
analyze the human gene-centric 50K bead chip (IBC array),
which focuses on loci with a potential functional link to
cardiovascular disease (CVD) and covers more than 45,000 SNPs
from about 2,000 genes [6].
Our study identified a polymorphism (rs1739843) in intron 2 of
the HSPB7 gene being associated with susceptibility to DCM in a
German case-control sample with three replication steps. Recent-
ly, Cappola et al. reported an association between rs1739843 and
both, ischemic and non-ischemic heart failure, applying the same
gene-centric 50K bead chip [7]. They found a protective effect of
the minor allele, which is in conformity with our results on DCM.
As DCM is a potential preliminary stage for non-ischemic heart
failure, these independent findings point to a possible common
pathophysiologic cascade. However, a second association signal
for heart failure located in the FRMD4B region (rs6787362, minor
allele frequency (MAF) 10.4%) identified by Cappola et al. [7]
could not be detected in our DCM case-control sample (p=0.64).
Our study had a power of 99% to find a nominal association
between DCM and rs6787362 with p,0.05 and an OR=0.67.
The finding on HSPB7 is also in-line with a previously reported
large-scale re-sequencing approach in four biologically relevant
cardiac signaling genes, which detected HSPB7 sequence diversity
in sporadic cardiomyopathy [8]. Our data together with the results
from Cappola et al. [7] and Matkovich et al. [8], substantiate the
importance of rs1739843 or related polymorphisms in the HSPB7
locus for DCM and heart failure and possibly underscore a
common genetic basis for these related phenotypes.
Matkovich et al. further report that none of the detected HSPB7
gene variants altered amino acid sequence [8], which is also
consistent with the fact that we found neither missense nor splice
site mutations in the HSPB7 sequence. Therefore, the biological
mechanism explaining the association between the polymorphism
rs1739843 and DCM risk remains still unclear. The three detected
synonymous variants (rs945416, rs732286 and rs1739840) are in
high LD with each other as well as with our lead SNP rs1739843
and lie on one LD block. Therefore, it could be hypothesized that
these SNPs represent causal risk factors for DCM, as described for
the P-glycoprotein encoding gene MCP1 and affected drug and
inhibitor interactions [9]. Synonymous SNPs lead to changes in
codon usage and may cause functional implications by conforma-
tional changes in protein structure due to translation efficiency.
Alternatively, a de novo splice site could be created by a SNP or
other (unmapped) polymorphisms outside the HSPB7 coding
region may alter its gene expression. Clearly, functional studies
would be required to prove these hypotheses.
Besides the HSPB7 gene, where the lead SNP is located, also five
genes (CLCNKA, CLCNKB, C1orf64, ZBTB17 and SPEN) lying on
the same LD block may potentially be responsible for the
association with DCM. CLCNKA and CLCNKB encode for two
members of the family of voltage-gated chloride channels. These
proteins are predominantly expressed in the kidney and participate
in renal salt reabsorption [10]. The function of C1orf64 is currently
unknown. ZBTB17, also known as MIZ-1, encodes a zinc finger
protein involved in the regulation of c-myc [11]. SPEN (RBM15C
or MINT) encodes a conserved transcriptional repressor that
controls the expression of regulators in diverse signaling pathways
[12,13].
HSPB7, encoding the small heat shock protein cvHsp (also
known as HspB7), is the functionally most plausible candidate
gene in this genomic region. It is known to be expressed in
cardiovascular and insulin-sensitive tissues [14]. In general, the
expression and activation of heat shock proteins is influenced by
elevated temperatures as well as ischemia, hypoxia and acute
cellular stress [15,16]. In the aging skeletal muscle increase of
cvHsp protein content was observed [17]. cvHsp was shown to be
constitutively localized under non-stressful conditions to nuclear
splicing speckles and may influence mRNA processing [18].
Recent data suggest co-localization between cvHsp and a-B-
crystallin in the z-band of cardiac tissue and interaction with other
small heat shock proteins [19]. However, further investigations like
genomic fine-mapping and subgroup analyses in the context of
cardiomyopathies are needed.
Genetic analyses in familial forms of DCM led to the
identification of risk loci showing X-linked, autosomal dominant
or autosomal recessive patterns of inheritance [2,20,21]. Some of
the DCM causing genes or plausible candidate genes were also
covered by the 50K bead chip, wherefore we specifically tested
those SNPs lying in risk gene regions (10 kb upstream and
downstream, respectively). In these analyses, no significant
association with any of the gene variants was found, indicating
that in sporadic cases of DCM probably other pathways are
involved than in familial DCM. However, less frequent variants
may have been missed due to insufficient power of our screening
sample. Furthermore, the distinction between familial and
sporadic forms of DCM is, to a certain degree, somewhat
arbitrary. Screening of family members is rarely done in clinical
routine, but when carried out on a systematic basis, up to 7% of
previously healthy first-degree relatives have reduced left ventric-
ular function or dilation without presence of cardiac symptoms
[22]. Therefore, it might be anticipated that genetic testing could
help to identify individuals at risk in familial DCM but also in
families of patients affected by so-called idiopathic forms of the
disease.
Already known genetic factors account for only a fraction of
DCM heritability [20]. Given a 1.5-fold increased risk of DCM
among heterozygous subjects in our screening sample (48% in the
general population-based KORA study) and a 2.25 times
increased risk among homozygous subjects (34% in KORA),
49% of DCM cases would be attributable to the SNP rs1739843
(or correlated polymorphisms) with 19% attributable to heterozy-
gous and 30% to homozygous carriers, respectively. Therefore, the
genetic component seems to comprise a large proportion for this
disease. However, with the prevalence of the idiopathic form of the
disease being about 1:2,700 [23], a genetic screening of the general
population would include four cases out of 10,000 screened
persons and two of these would have the disease due to this SNP.
Therefore, the great potential of this variant might rather be
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potential drug targets. Further investigations should aim (1) to
identify additional variants underlying DCM susceptibility with
otherwise unknown etiology and (2) to analyze potential influence of
thesecommonallelesasmodifiersforfamilialformsofDCM.Taken
together for both, modifiers of familial forms and susceptibility
alleles in idiopathic DCM, knowledge of genetic background will
support preventive medical measures in the future.
Some limitations of our study should be mentioned. First, we
conducted a large-scale SNP analysis focused on genes potentially
involved in cardiovascular traits. Therefore, on the one hand we
were able to detect associations between DCM and polymor-
phisms only in these pre-selected genes. On the other hand, the
50K human CVD bead chip allows comprehensive gene-based
analysis with more than 2,000 well covered loci. Second, our
sample size only allowed to detect moderate to large effects (e. g.
for OR.1.3 and MAF=30% or OR.1.5 and MAF=20% or
OR.1.7 and MAF=10%, the power was 19%, 75% and 80% for
p,2.15*10
26, respectively). Therefore, we may have overlooked
real association signals in our screening step. Third, there could be
some population stratification in our initial screen sample.
However, the observed l could also be caused - in part - by
underlying association due to the analysis of pre-selected loci
known or suggested to be involved in cardiovascular phenotypes.
The fact that the association between rs1739843 in HSPB7 and
idiopathic DCM was replicated in three independent samples
strongly enhances the confidence in our results.
Materials and Methods
Ethics statement
The ethics committees of the participating study centers
approved the study protocol and all participants gave their written
informed consent. The study was in accordance with the principles
of the current version of the Declaration of Helsinki.
Case-control samples and phenotyping
Cases for the initial German screening study were recruited from
the German Heart Institute (Berlin), and controls were from a
population-based German KORA study (follow-up survey F3,
Augsburg) [24]. Phenotypic details are summarized in Table 1.
Controls (n=1,874) had no medical history for coronary artery
disease (CAD), myocardial infarction or DCM; mean age was
62611 years and slightly more women (n=986) than men (n=888)
were present in the control group. Inclusion criteria for DCM cases
were the following: reduced systolic function (left ventricular
ejection fraction (LVEF) ,45%) without angiographically assessed
evidence of major CAD, significant valvular heart disease (.grade
2, i. e. such as mitral or aortic regurgitation), hypertensive heart
disease, congenital heart disease, myocarditis (by endomyocardial
biopsy, when available) or other secondary forms of heart failure.
Patients with a positive family history were also excluded from this
study. In DCM cases (n=664), mean LVEF was 2463% and mean
age of disease diagnosis was 46611 years.
For the first replication step, additional German DCM cases
(mean age 53613 years; n=564, n=440 men, n=124 women)
were recruited from different German study centers: Berlin,
n=64; Lu ¨beck, n=96 (Angio-Lueb); Marburg, n=61 (EURO-
GENE); Mu ¨nster, n=101 (EUROGENE); Regensburg, n=150
(EUROGENE); Regensburg, n=92 (GoKard). Independent
German KORA controls from surveys S1 and S2 (n=981,
n=539 men, n=442 women) had a mean age of 52610 years
[24]. Inclusion and exclusion criteria were identical to the initial
case-control sample.
A second replication study (France 1) was recruited in France
(CARDIGENE) [25,26]. The French cases were of white European
origin (all born in France, from parents born in France or
neighboring countries) with a diagnosis of DCM, i. e. enlarged left
ventricle end-diastolic volume/diameter .140 ml/m
2 on ventric-
ulography or .34 mm/m
2 on echocardiography and LVEF#40%
confirmed over a six-month period, in the absence of causal factors
such as CAD or sustained hypertension, intrinsic valvular disease,
documented myocarditis, congenital malformation, insulin-depen-
dent diabetes. Only apparently sporadic DCM cases without
additional (first degree) relative with DCM were included (but 8%
were in fact with familial form after careful cardiac examination in
relatives). Recruitment was performed in ten hospitals in six regions
in France (Lille, Lyon, Nancy, Nantes, Paris-Ile de France,
Strasbourg) from September 1994 to February 1996. A total of
433 patients (229 had undergone a cardiac transplantation) were
included (n=345 men, n=88 women). Mean age of patients was
45611 years, mean LVEF was 2367% and mean end-diastolic
volume was 195667 ml/m
2. Controls (n=395) were age- and
gender-matched (n=310 men, n=85 women).
The third replication sample was also of French origin (France
2). Inclusion criteria were identical to the France 1 sample. A total
of 249 patients from EUROGENE and PHRC were included
(n=198 men, n=51 women). Mean age of patients at diagnosis
was 51610 years. Controls (n=380) were free of medical history
for CAD, myocardial infarction or DCM and mean age was
46611 years (n=301 men, n=79 women).
Genotyping
Initial genotyping was carried out using the 50K gene-centric
human CVD bead chip version 1 (IBC v1 array) (Illumina, San
Diego, CA, USA) [6] following the manufacturer’s protocol. Data
were analyzed (calling and sample clustering) and exported
employing BeadStudio analysis software (Illumina). From the
initial 45,707 SNPs, those markers with low call rates (,95%) or
low frequency (MAF,1%) were excluded. Minimal call rate per
individual was 90%. We used identity-by-descent methods to
exclude unknown first-degree relation of participants.
Replication samples were taken from human CVD bead chip
data or genotyped with 59 exonuclease TaqMan technology
(Applied Biosystems, Foster City, CA, USA) as previously des-
cribed [27]. A by-design assay for rs1739843 was used with primer
sequences 59-CTCTGCCATCACCATCTCACA-39 and 59-GG-
CAGAGGGAGCCTGAG-39 and probe sequences 59-VIC-AG-
GGTGGGAGGTGACAG-NFQ-39 and 59-FAM-AGGGTGG-
GAGATGACAG-NFQ-39 (site of rs1739843 is underlined;
fluorescence dyes VIC and FAM on 59 end and non-fluorescence
quencher (NFQ) on 39 end are indicated). All other assays
were obtained pre-designed directly from Applied Biosystems.
Detailed information on assays used in France 2 sample are
available at http://genecanvas.ecgene.net/infusions/genecanvas/
Polymorphisms/PolymorphismsList.php.
SNP rs1739843 was re-genotyped using the by-design TaqMan
assay in initial case sample (n=664) to check for discrepancies
between human CVD bead chip and TaqMan genotypes. A
.99.8% concordance of genotypes was found. For all genotyped
samples a call rate .97% for each SNP assay was reached.
Resequencing
Polymerase chain reaction (PCR) primer were generated using
Primer3Plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/
primer3plus.cgi) [28] to cover the coding parts of the three HSPB7
exons (GenBank accession No. NM_14424.4). The primer
sequences and PCR amplification products are listed in Table
Genetic Association with DCM
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156 bp for 39 end of intron 1, 136 bp for 59 end of intron 2, and
89 bp for 39 end of intron 2, respectively. PCR cycling conditions
consisted of an initial denaturation at 95uC for 9 min, followed by
40 cycles with denaturation at 95uC for 30 s, annealing at 60uC for
30 s, and elongation at 72uC for 30 s, with a final elongation step
at 72uC for 7 min.
After PCR amplification, primers and dNTPs were removed
using ExoSAP-IT (USB Europe, Staufen, Germany) following the
manufacturer’s instructions. The purified PCR products were
directly sequenced using the ABI PRISM BigDye Terminator
Cycle Sequencing Ready Reaction Kit Version 3.1 on the ABI
3730 (Applied Biosystems, Foster City, CA, USA).
Statistical analyses
For initial screening and replication analyses, logistic regression
adjusted for gender was used. P-values, odds ratios (OR) and their
95% confidence intervals (CI) were reported. The inflation factor
l was computed in the 50K initial screening analysis for logistic
regression analysis assuming a x
2 distribution with two degrees of
freedom of the minus two-times logep measures (90% highest p-
values). The p-values and CI from initial screening analysis were
genomic-control corrected using this l factor via standard errors
(standard error[corrected]=sqrt(l)*standard error) and beta esti-
mates (95%CI beta[corrected]=beta61.96*standard error[corrected]).
Deviation from Hardy-Weinberg equilibrium was calculated with
an exact test [29]. Statistical and association analyses were
performed using JMP 7.0.2 (SAS Institute Inc, Cary, NC, USA)
and PLINK v1.07 (http://pngu.mgh.harvard.edu/,purcell/
plink/) [30], respectively. Power analysis was carried out using
Quanto 1.2.4 (http://hydra.usc.edu/gxe/). We combined the
initial scan results corrected for l with the replication studies’
results using a fixed effect model. Annotation of association results
on a genome level was performed with WGAViewer soft-
ware (http://people.genome.duke.edu/,dg48/WGAViewer/) [31].
LD patterns were calculated using HapMap releases #22 and #24
(http://www.hapmap.org/) [32].
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